Literature DB >> 26077199

Changing the Paradigm - Treating the Basic Defect in Cystic Fibrosis.

Lokesh Guglani1.   

Abstract

Since the first description of Cystic fibrosis (CF) more than 75 y ago, significant advances have been made in understanding its pathogenesis and in developing specific therapies. The pace of these developments was further accelerated after the discovery of CF gene in 1989 and since then, CF has been transformed from being a pediatric illness into a chronic life-limiting genetic disorder with survival up to the fourth decade. The development of mutation-specific therapies in the first decade of the 21st century has the potential to change the natural history of CF and has now ushered in the era of 'Precision Medicine'. The ability to revert the basic defect in CF by using Personalized Medicine approach based on each individual's genetic profile will serve as a model for other chronic disorders as well. This review highlights the recent advances in the field of CF research that have led to a paradigm shift in its management and outcomes.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26077199     DOI: 10.1007/s12098-015-1786-3

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  38 in total

1.  Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.

Authors:  Patrick A Flume; Theodore G Liou; Drucy S Borowitz; Haihong Li; Karl Yen; Claudia L Ordoñez; David E Geller
Journal:  Chest       Date:  2012-09       Impact factor: 9.410

2.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

3.  A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function.

Authors:  R C Rubenstein; P L Zeitlin
Journal:  Am J Respir Crit Care Med       Date:  1998-02       Impact factor: 21.405

4.  Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists.

Authors:  L V Galietta; S Jayaraman; A S Verkman
Journal:  Am J Physiol Cell Physiol       Date:  2001-11       Impact factor: 4.249

5.  Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression.

Authors:  Guido Veit; Radu G Avramescu; Doranda Perdomo; Puay-Wah Phuan; Miklos Bagdany; Pirjo M Apaja; Florence Borot; Daniel Szollosi; Yu-Sheng Wu; Walter E Finkbeiner; Tamas Hegedus; Alan S Verkman; Gergely L Lukacs
Journal:  Sci Transl Med       Date:  2014-07-23       Impact factor: 17.956

6.  A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.

Authors:  Michael P Boyle; Scott C Bell; Michael W Konstan; Susanna A McColley; Steven M Rowe; Ernst Rietschel; Xiaohong Huang; David Waltz; Naimish R Patel; David Rodman
Journal:  Lancet Respir Med       Date:  2014-06-24       Impact factor: 30.700

Review 7.  Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases.

Authors:  Kavitha Siva; Giuseppina Covello; Michela A Denti
Journal:  Nucleic Acid Ther       Date:  2014-02       Impact factor: 5.486

8.  CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium.

Authors:  Liqun Zhang; Brian Button; Sherif E Gabriel; Susan Burkett; Yu Yan; Mario H Skiadopoulos; Yan Li Dang; Leatrice N Vogel; Tristan McKay; April Mengos; Richard C Boucher; Peter L Collins; Raymond J Pickles
Journal:  PLoS Biol       Date:  2009-07-21       Impact factor: 8.029

9.  VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1.

Authors:  Hong Yu Ren; Diane E Grove; Oxana De La Rosa; Scott A Houck; Pattarawut Sopha; Fredrick Van Goor; Beth J Hoffman; Douglas M Cyr
Journal:  Mol Biol Cell       Date:  2013-08-07       Impact factor: 4.138

10.  CFTR and Anoctamin 1 (ANO1) contribute to cAMP amplified exocytosis and insulin secretion in human and murine pancreatic beta-cells.

Authors:  Anna Edlund; Jonathan L S Esguerra; Anna Wendt; Malin Flodström-Tullberg; Lena Eliasson
Journal:  BMC Med       Date:  2014-05-28       Impact factor: 8.775

View more
  3 in total

1.  Editorial: Advances in Pediatric Pulmonology.

Authors:  Andrew Bush; Sushil K Kabra
Journal:  Indian J Pediatr       Date:  2015-06-19       Impact factor: 1.967

Review 2.  Neutrophil Adaptations upon Recruitment to the Lung: New Concepts and Implications for Homeostasis and Disease.

Authors:  Vincent D Giacalone; Camilla Margaroli; Marcus A Mall; Rabindra Tirouvanziam
Journal:  Int J Mol Sci       Date:  2020-01-28       Impact factor: 5.923

Review 3.  Role of Cellular Metabolism in the Formation of Neutrophil Extracellular Traps in Airway Diseases.

Authors:  Gabriel Morán; Benjamín Uberti; John Quiroga
Journal:  Front Immunol       Date:  2022-04-12       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.